Reference : Selection of data sets for FAIRification in drug discovery and development: Which, wh...
Scientific journals : Article
Life sciences : Multidisciplinary, general & others
Systems Biomedicine
http://hdl.handle.net/10993/51048
Selection of data sets for FAIRification in drug discovery and development: Which, why, and how?
English
Alharbi, Ebtisam [> >]
Gadiya, Yojana [> >]
Henderson, David [> >]
Zaliani, Andrea [> >]
Delfin-Rossaro, Alejandra [> >]
Cambon-Thomsen, Anne [> >]
Kohler, Manfred [> >]
Witt, Gesa [> >]
Welter, Danielle mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core]
Juty, Nick [> >]
Jay, Caroline [> >]
Engkvist, Ola [> >]
Goble, Carole [> >]
Reilly, Dorothy S. [> >]
Satagopam, Venkata mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core]
Ioannidis, Vassilios [> >]
Gu, Wei mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core]
Gribbon, Philip [> >]
2022
Drug Discovery Today
Yes (verified by ORBilu)
International
1359-6446
[en] FAIR ; FAIRification ; Pharmaceutical R&D ; Drug discovery ; Cost–benefit
[en] Despite the intuitive value of adopting the Findable, Accessible, Interoperable, and Reusable (FAIR) principles in both academic and industrial sectors, challenges exist in resourcing, balancing long- versus short-term priorities, and achieving technical implementation. This situation is exacerbated by the unclear mechanisms by which costs and benefits can be assessed when decisions on FAIR are made. Scientific and research and development (R&D) leadership need reliable evidence of the potential benefits and information on effective implementation mechanisms and remediating strategies. In this article, we describe procedures for cost–benefit evaluation, and identify best-practice approaches to support the decision-making process involved in FAIR implementation.
Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group)
European Commission - EC
IMI-FAIRplus
Researchers ; Professionals
http://hdl.handle.net/10993/51048
10.1016/j.drudis.2022.05.010
https://www.sciencedirect.com/science/article/pii/S1359644622001994

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
DRUDIS-S-22-00010-1.pdfAuthor preprint648.55 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.